MiRNA-378 Is Downregulated by XBP1 and Inhibits Growth and Migration of Luminal Breast Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jan 11

PMID 38203358

Authors

Vahid Arabkari

David Barua

Muhammad Mosaraf Hossain

Mark Webber

Terry Smith

Ananya Gupta

Sanjeev Gupta

Affiliations

Soon will be listed here.

Abstract

X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR), a cellular stress response pathway involved in maintaining protein homeostasis in the endoplasmic reticulum (EnR). While the role of XBP1 in UPR is well-characterised, emerging evidence suggests its involvement in endocrine resistance in breast cancer. The transcriptional activity of spliced XBP1 (XBP1s) is a major component of its biological effects, but the targets of XBP1s in estrogen receptor (ER)-positive breast cancer are not well understood. Here, we show that the expression of miR-378 and PPARGC1B (host gene of miR-378) is downregulated during UPR. Using chemical and genetic methods, we show that XBP1s is necessary and sufficient for the downregulation of miR-378 and PPARGC1B. Our results show that overexpression of miR-378 significantly suppressed cell growth, colony formation, and migration of ER-positive breast cancer cells. Further, we found that expression of miR-378 sensitised the cells to UPR-induced cell death and anti-estrogens. The expression of miR-378 and PPARGC1B was downregulated in breast cancer, and higher expression of miR-378 is associated with better outcomes in ER-positive breast cancer. We found that miR-378 upregulates the expression of several genes that regulate type I interferon signalling. Analysis of separate cohorts of breast cancer patients showed that a gene signature derived from miR-378 upregulated genes showed a strong association with improved overall and recurrence-free survival in breast cancer. Our results suggest a growth-suppressive role for miR-378 in ER-positive breast cancer where downregulation of miR-378 by XBP1 contributes to endocrine resistance in ER-positive breast cancer.

Citing Articles

Potential therapies for non-coding RNAs in breast cancer.

Li R, Ji Y, Ye R, Tang G, Wang W, Chen C Front Oncol. 2024; 14:1452666.

PMID: 39372872 PMC: 11449682. DOI: 10.3389/fonc.2024.1452666.

The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis.

Liu Y, Dong L, Ma J, Chen L, Fang L, Wang Z Clin Exp Med. 2024; 24(1):113.

PMID: 38795164 PMC: 11127859. DOI: 10.1007/s10238-024-01372-6.

Decoding contextual crosstalk: revealing distinct interactions between non-coding RNAs and unfolded protein response in breast cancer.

Karamali N, Daraei A, Rostamlou A, Mahdavi R, Jonoush Z, Ghadiri N Cancer Cell Int. 2024; 24(1):104.

PMID: 38468244 PMC: 10926595. DOI: 10.1186/s12935-024-03296-3.

References

Hu R, Warri A, Jin L, Zwart A, Riggins R, Fang H . NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Mol Cell Biol. 2014; 35(2):379-90. PMC: 4272419. DOI: 10.1128/MCB.00847-14. View

Davies M, Barraclough D, Stewart C, Joyce K, Eccles R, Barraclough R . Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer. 2008; 123(1):85-8. DOI: 10.1002/ijc.23479. View

Barua D, Gupta A, Gupta S . Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges. Cancer Lett. 2020; 486:29-37. DOI: 10.1016/j.canlet.2020.05.020. View

Avgeris M, Stravodimos K, Scorilas A . Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biol Chem. 2014; 395(9):1095-104. DOI: 10.1515/hsz-2014-0150. View

Deng Z, Du W, Fang L, Shan S, Qian J, Lin J . The intermediate filament vimentin mediates microRNA miR-378 function in cellular self-renewal by regulating the expression of the Sox2 transcription factor. J Biol Chem. 2012; 288(1):319-31. PMC: 3537029. DOI: 10.1074/jbc.M112.418830. View

Tan D, Zhou C, Han S, Hou X, Kang S, Zhang Y . MicroRNA-378 enhances migration and invasion in cervical cancer by directly targeting autophagy-related protein 12. Mol Med Rep. 2018; 17(5):6319-6326. PMC: 5928611. DOI: 10.3892/mmr.2018.8645. View

Gomez B, Riggins R, Shajahan A, Klimach U, Wang A, Crawford A . Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007; 21(14):4013-27. DOI: 10.1096/fj.06-7990com. View

Read D, Gupta A, Ladilov Y, Samali A, Gupta S . miRNA signature of unfolded protein response in H9c2 rat cardiomyoblasts. Cell Biosci. 2014; 4(1):56. PMC: 4190440. DOI: 10.1186/2045-3701-4-56. View

Qiu P, Xu T, Lu X, Yang W, Zhang Y, Xu G . MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma. Oncol Lett. 2018; 15(1):789-794. PMC: 5772874. DOI: 10.3892/ol.2017.7431. View

10.

Li W, Liu Y, Yang W, Han X, Li S, Liu H . MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. J Neurooncol. 2017; 136(1):63-71. PMC: 5922763. DOI: 10.1007/s11060-017-2646-y. View

11.

Ji K, Cui F, Qu D, Sun R, Sun P, Chen F . MiR-378 promotes the cell proliferation of non-small cell lung cancer by inhibiting FOXG1. Eur Rev Med Pharmacol Sci. 2018; 22(4):1011-1019. DOI: 10.26355/eurrev_201802_14383. View

12.

Yu B, Peng X, Zhao F, Liu X, Lu J, Wang L . MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 2014; 44(4):1215-22. DOI: 10.3892/ijo.2014.2283. View

13.

Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T . miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 2015; 5:13170. PMC: 4530347. DOI: 10.1038/srep13170. View

14.

Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee A, Yoshida H . XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004; 64(17):5943-7. DOI: 10.1158/0008-5472.CAN-04-1606. View

15.

Winsel S, Maki-Jouppila J, Tambe M, Aure M, Pruikkonen S, Salmela A . Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo. Br J Cancer. 2014; 111(11):2142-51. PMC: 4260036. DOI: 10.1038/bjc.2014.524. View

16.

Wang Z, Ma B, Ji X, Deng Y, Zhang T, Zhang X . MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. Cancer Cell Int. 2015; 15:40. PMC: 4431608. DOI: 10.1186/s12935-015-0192-2. View

17.

Hetz C . The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012; 13(2):89-102. DOI: 10.1038/nrm3270. View

18.

Barua D, Abbasi B, Gupta A, Gupta S . XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation. Heliyon. 2020; 6(10):e05217. PMC: 7557884. DOI: 10.1016/j.heliyon.2020.e05217. View

19.

Skrzypek K, Tertil M, Golda S, Ciesla M, Weglarczyk K, Collet G . Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid Redox Signal. 2013; 19(7):644-60. PMC: 3740397. DOI: 10.1089/ars.2013.5184. View

20.

Andruska N, Zheng X, Yang X, Helferich W, Shapiro D . Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer. Oncogene. 2014; 34(29):3760-9. PMC: 4377305. DOI: 10.1038/onc.2014.292. View